News | Prostate Cancer | December 19, 2017

BIO 300 from Humanetics Corp. under development as adjunct therapy in combination with radiation therapy for prevention of radiation-induced erectile dysfunction in prostate cancer patients

New Data Examines Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients

December 19, 2017 — Humanetics Corp. presented data at the annual meetings of the American Society for Radiation Oncology (ASTRO) and the Radiation Research Society (RRS), on the company’s new drug candidate, BIO 300, which is being evaluated as a potential treatment to prevent erectile dysfunction in patients undergoing radiotherapy for prostate cancer. The annual ASTRO meeting was held Sept. 24-27 in San Diego, and the annual RRS meeting was held Oct. 15-18 in Cancun, Mexico; Zeljko Vujaskovic, M.D., Ph.D., a professor of radiation oncology at the University of Maryland School of Medicine (UMSOM) and director of the school’s Division of Translational Radiation Sciences, and Michael Kaytor, Ph.D., vice president of research and development at Humanetics, presented data at the respective meetings.

Prostate cancer is the most common non-skin cancer affecting men in the U.S. According to the National Cancer Institute (NCI), nearly 162,000 men will be diagnosed with prostate cancer in the U.S. in 2017, representing approximately 20 percent of all new cancers in men. While survival rates are high, radiation-induced erectile dysfunction (ED) is a common and lingering side effect associated with prostate radiotherapy. Nearly half of all men undergoing radiation treatment for prostate cancer will experience some level of ED.

Data presented included the results of nonclinical studies that were conducted at UMSOM. These studies demonstrated the potential of BIO 300 to both mitigate radiation-induced ED and also to improve the effectiveness of radiation therapy to kill tumors. “These compelling results show the promise of BIO 300 to enhance a prostate cancer patient’s quality of life, while also directly impacting the ability of radiation therapy to kill the tumor,” said Vujaskovic. “If this result can be translated to the clinical treatment of prostate cancer, it would represent a breakthrough in prostate cancer treatment outcomes.”

At present, there are no U.S. Food and Drug Administration (FDA)-approved drugs to mitigate radiation-induced ED. “BIO 300’s potential to enhance radiation’s killing effect on the tumor while reducing treatment-related side effects is unparalleled,” said Kaytor. “These findings support the advancement of BIO 300 into a human efficacy study, which is anticipated to begin in 2018.”

BIO 300 is in development for prevention and mitigation of toxicities associated with radiation exposure for the treatment of multiple cancers and is currently in a Phase Ib/IIa clinical trial in patients with non-small cell lung cancer who are receiving chemoradiotherapy.

For more information: www.humaneticscorp.com


Related Content

Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
News | Artificial Intelligence

March 21, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time March 21, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Artificial Intelligence

February 26, 2024 — DeepHealth, Inc., one of the leading providers in healthcare radiology informatics, has today ...

Time February 26, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
Subscribe Now